Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

USING THE NODE 18+ NATIVE TEST RUNNER WITH TYPESCRIPT AND REACT

Node.js 18 introduced a native test runner that can replace Jest, Mocha, or Vitest for basic testing scenarios, including TypeScript and React component testing. The setup requires minimal configuration with experimental flags for TypeScript support and module mocking, plus dependencies like `tsx`, `global-jsdom`, and `@testing-library/react`. While it has advantages like no config files and a smaller dependency footprint, it has limitations like having a smaller ecosystem compared to established testing frameworks.

HYBRIDPETYA RANSOMWARE BYPASSES UEFI SECURE BOOT ECHOING PETYA/NOTPETYA

The HybridPetya ransomware on VirusTotal echoes the infamous Petya/NotPetya attacks but adds UEFI bootkit capabilities and exploits CVE-2024-7344 to bypass UEFI Secure Boot on outdated systems. Unlike NotPetya, HybridPetya functions as actual ransomware with decryption capabilities, encrypting the Master File Table after compromising EFI partitions and displaying fake CHKDSK status before showing ransom demands. This marks the fourth known UEFI bootkit with Secure Boot bypass capability, joining BlackLotus, BootKitty, and the Hyper-V Backdoor PoC, indicating these sophisticated attacks are becoming more common.

ELON MUSK'S BORING COMPANY COMPLETES VEGAS LOOP TUNNEL TO AIRPORT

The Boring Company has successfully completed a 2.26-mile tunnel for the Vegas Loop system in Las Vegas. The tunnel, aimed at alleviating surface congestion in one of America's busiest tourist destinations, stretches from a site near Harry Reid International Airport in the south to the Westgate Resort in the north. There will be eight stations along the route, including key stops at Virgin hotels and the Hughes Center. The tunnel is part of a broader plan to create a 68-mile network with over 100 stations to connect major landmarks.

PROMISING NEW EPILEPSY DRUG DELIVERS 80% REDUCTION IN SEIZURES

Rapport Therapeutics' experimental compound, RAP-219, reduced seizures by an average of 77.8% in a Phase 2a study. Almost a quarter of participants remained seizure-free over the two-month treatment period. The study raises hopes for patients who suffer from seizures despite being on multiple medications. Rapport plans to meet with the US Food and Drug Administration and then launch two Phase 3 trials next year. It is also developing a long-acting injectable version to address medication adherence, a frequent challenge in epilepsy.

TLDR IndexPage 1